JP7039083B1 - Ampk活性化剤 - Google Patents
Ampk活性化剤 Download PDFInfo
- Publication number
- JP7039083B1 JP7039083B1 JP2021124108A JP2021124108A JP7039083B1 JP 7039083 B1 JP7039083 B1 JP 7039083B1 JP 2021124108 A JP2021124108 A JP 2021124108A JP 2021124108 A JP2021124108 A JP 2021124108A JP 7039083 B1 JP7039083 B1 JP 7039083B1
- Authority
- JP
- Japan
- Prior art keywords
- ampk
- colloid
- platinum
- palladium
- ampk activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
[1]白金コロイドとパラジウムコロイドとを含有する、AMPK活性化剤。
[2]白金コロイドとパラジウムコロイドとを含有する、長寿延命剤。
[3]白金コロイドとパラジウムコロイドとを含有する、抗老化剤。
[4]白金コロイドとパラジウムコロイドとを含有する、酵素活性化剤。
[5]白金コロイドとパラジウムコロイドとを含有する、細胞周期制御剤。
[6]白金コロイドとパラジウムコロイドとを含有する、ミトコンドリア活性化剤。
[7]白金コロイドとパラジウムコロイドとを含有する、ATP産生恒常性持続剤。
[8]白金コロイドとパラジウムコロイドとを含有する、免疫応答機能調節剤。
CycLex(登録商標) AMPK Kinase Assay Kit(MBL社製)を用いて、以下の条件で、AMPK活性促進効果を調べた。検体群として、PAPLAL(登録商標)水(6mlの液剤中、白金コロイドを1.2mg、パラジウムコロイドを1.8mg含む。)を1%添加した群を平板法により作製した。具体的には、PAPLAL(登録商標)水を減菌し、培養液で10倍に希釈することにより調製した10%パプラール溶液1mLを、フラスコにて培養した乳がん細胞の培養液9mLに対して添加することにより、検体群を作製した。また、コントロール群としては、PAPLAL(登録商標)水に変えて超純水を1%添加した群を用いた。
使用キット:CycLex(登録商標) AMPK Kinase Assay Kit
使用試薬:Microplate, 10X Wash Buffer, Kinase Buffer, 20X ATP, 20X DTT, Anti-phospho-mouse IRS-1 S789 Monoclonal Antibody(AS-4C4), HRP conjugated Anti-mouse IgG, Substrate Reagent, Stop Solution
使用細胞:ヒト乳がん細胞(MCF-7)5×106個
培養条件:37℃、5%CO2にてインキュベート
1時間後:P=0.00307
12時間後:P=0.00897
24時間後:P=0.0000311
Claims (1)
- 白金コロイドとパラジウムコロイドとを含有する、AMPK活性化剤(但し、抗老化剤を除く)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021124108A JP7039083B1 (ja) | 2021-07-29 | 2021-07-29 | Ampk活性化剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021124108A JP7039083B1 (ja) | 2021-07-29 | 2021-07-29 | Ampk活性化剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP7039083B1 true JP7039083B1 (ja) | 2022-03-22 |
JP2023019411A JP2023019411A (ja) | 2023-02-09 |
Family
ID=81214282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021124108A Active JP7039083B1 (ja) | 2021-07-29 | 2021-07-29 | Ampk活性化剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7039083B1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001010954A (ja) * | 1999-06-29 | 2001-01-16 | Otsuka Sangyo Kk | 酸化的ストレスに対する保護剤 |
WO2004073722A1 (ja) * | 2003-02-20 | 2004-09-02 | Shetech Co., Ltd. | スーパーオキサイドアニオン分解剤 |
JP6343851B1 (ja) * | 2017-07-28 | 2018-06-20 | 株式会社東洋厚生製薬所 | 抗ピロリ菌剤 |
JP6635319B1 (ja) * | 2018-07-31 | 2020-01-22 | 株式会社東洋厚生製薬所 | ナチュラルキラー細胞活性化剤 |
-
2021
- 2021-07-29 JP JP2021124108A patent/JP7039083B1/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001010954A (ja) * | 1999-06-29 | 2001-01-16 | Otsuka Sangyo Kk | 酸化的ストレスに対する保護剤 |
WO2004073722A1 (ja) * | 2003-02-20 | 2004-09-02 | Shetech Co., Ltd. | スーパーオキサイドアニオン分解剤 |
JP6343851B1 (ja) * | 2017-07-28 | 2018-06-20 | 株式会社東洋厚生製薬所 | 抗ピロリ菌剤 |
JP6635319B1 (ja) * | 2018-07-31 | 2020-01-22 | 株式会社東洋厚生製薬所 | ナチュラルキラー細胞活性化剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2023019411A (ja) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maddocks et al. | Metabolic regulation by p53 | |
Cabrera | Zinc, aging, and immunosenescence: an overview | |
Duntas et al. | Selenium: an element for life | |
Običan et al. | Folic acid in early pregnancy: a public health success story | |
Novío et al. | Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint‐stressed mice | |
Kim et al. | Inhibition of p38 and ERK MAP kinases blocks endotoxin-induced nitric oxide production and differentially modulates cytokine expression | |
Qureshi et al. | Inhibition of nitric oxide in LPS-stimulated macrophages of young and senescent mice by δ-tocotrienol and quercetin | |
Aihara et al. | Effects of N-acetylcysteine and ambroxol on the production of IL-12 and IL-10 in human alveolar macrophages | |
Bemiss et al. | Interleukin-2 is one of the targets of 1, 25-dihydroxyvitamin D3 in the immune system | |
Fu et al. | Effect of selenium antagonist lead-induced damage on Th1/Th2 imbalance in the peripheral blood lymphocytes of chickens | |
Austin et al. | A community randomized controlled clinical trial of mixed carotenoids and micronutrient supplementation of patients with acquired immunodeficiency syndrome | |
US11911425B2 (en) | Anti-aging composition comprising a plant extract | |
Attaman et al. | The anti‐inflammatory impact of omega‐3 polyunsaturated Fatty acids during the establishment of endometriosis‐like lesions | |
De La Fuente et al. | Obesity as a model of premature immunosenescence | |
Chen et al. | Alpha-ketoglutarate (AKG) lowers body weight and affects intestinal innate immunity through influencing intestinal microbiota | |
Tsekhmistrenko et al. | Ecological and toxicological characteristics of selenium nanocompounds | |
Mastbergen et al. | Synthesis and release of human cartilage matrix proteoglycans are differently regulated by nitric oxide and prostaglandin-E2 | |
Allegra et al. | The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention | |
Kruber et al. | T-2 toxin is a cytochrome P450 1A1 inducer and leads to MAPK/p38-but not aryl hydrocarbon receptor-dependent interleukin-8 secretion in the human intestinal epithelial cell line Caco-2 | |
JP7039083B1 (ja) | Ampk活性化剤 | |
Kim et al. | Weissella cibaria CMU exerts an anti‑inflammatory effect by inhibiting Aggregatibacter actinomycetemcomitans‑induced NF‑κB activation in macrophages | |
Bai et al. | Folic acid absorption characteristics and effect on cecal microbiota of laying hens | |
Pintard et al. | Apocynin prevents GM-CSF-induced-ERK1/2 activation and-neutrophil survival independently of its inhibitory effect on the phagocyte NADPH oxidase NOX2 | |
Önal et al. | Escitalopram's inflammatory effect on the mammalian macrophages and its intracellular mechanism of action | |
JP6343851B1 (ja) | 抗ピロリ菌剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210729 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210729 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211006 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211222 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211222 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211228 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220125 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220201 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220302 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7039083 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |